{"id":"erydex-high-dose-dsp","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Insomnia / mood changes"},{"rate":null,"effect":"Osteoporosis (with chronic use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DSP (Dexamethasone Sodium Phosphate) is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors. The 'High dose' designation and proprietary formulation suggest optimization for systemic delivery and efficacy in severe inflammatory or autoimmune disorders. Quince Therapeutics' approach likely focuses on improved pharmacokinetics or reduced adverse effects compared to standard dexamethasone formulations.","oneSentence":"EryDex High dose DSP is a dexamethasone formulation designed for enhanced delivery and bioavailability in treating inflammatory and immune-mediated conditions.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:11:24.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe inflammatory or immune-mediated conditions (specific indication not publicly detailed in phase 3)"}]},"trialDetails":[{"nctId":"NCT03563053","phase":"PHASE3","title":"Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study","status":"TERMINATED","sponsor":"Quince Therapeutics S.p.A.","startDate":"2018-06-12","conditions":"Ataxia Telangiectasia, Genetic Syndrome","enrollment":104},{"nctId":"NCT02770807","phase":"PHASE3","title":"Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients","status":"COMPLETED","sponsor":"Quince Therapeutics S.p.A.","startDate":"2017-03-02","conditions":"Nervous System Disease, Genetic Syndrome","enrollment":176}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["EryDex System end product"],"phase":"phase_3","status":"active","brandName":"EryDex High dose DSP","genericName":"EryDex High dose DSP","companyName":"Quince Therapeutics S.p.A.","companyId":"quince-therapeutics-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EryDex High dose DSP is a dexamethasone formulation designed for enhanced delivery and bioavailability in treating inflammatory and immune-mediated conditions. Used for Severe inflammatory or immune-mediated conditions (specific indication not publicly detailed in phase 3).","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}